Literature DB >> 15118981

Galactose elimination capacity as a prognostic marker in patients with severe acetaminophen-induced hepatotoxicity: 10 years' experience.

Lars E Schmidt1, Peter Ott, Niels Tygstrup.   

Abstract

BACKGROUND & AIMS: Patients with acetaminophen-induced fulminant hepatic failure may have the capacity for recovery if sufficient liver cell mass remains to allow regeneration. We investigated the prognostic potential of the galactose elimination capacity (GEC) as a noninvasive measurement of functioning liver cell mass in severe acetaminophen-induced hepatotoxicity.
METHODS: All patients admitted with acetaminophen poisoning during a 10-year period were studied retrospectively. A total of 220 patients who had at least one GEC performed were included in the study.
RESULTS: The GEC was lower in patients with than without hepatic encephalopathy (14.5 +/- 5.6 micromol/min/kg vs. 23.2 +/- 6.7 micromol/min/kg; P < 0.0001). Among patients with hepatic encephalopathy, the GEC was significantly higher in spontaneous survivors than in nonsurvivors (16.8 +/- 5.6 micromol/min/kg vs. 12.2 +/- 4.7 micromol/min/kg; P < 0.0001). In a logistic regression analysis, GEC was associated independently with mortality (odds ratio: 1.28 per 1 micromol/min/kg decrease in GEC; 95% confidence interval: 1.14-1.45). A threshold GEC of 16.5 micromol/min/kg to identify nonsurvivors had a sensitivity of 90%, a specificity of 72%, a positive predictive value of 49%, and a negative predictive value of 96%. None of 14 patients with hepatic encephalopathy and a GEC less than 10 micromol/min/kg survived.
CONCLUSIONS: The GEC was strongly associated with development of hepatic encephalopathy and death from acetaminophen-induced fulminant hepatic failure. The GEC was too unspecific to be used alone for identification of transplantation candidates, but it may be useful as a supplement to other selection criteria.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15118981     DOI: 10.1016/s1542-3565(04)00128-4

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  11 in total

1.  Age-dependency of galactose elimination capacity in healthy children and children with chronic liver disease.

Authors:  Aksel Lange; Henning Grønbæk; Hendrik Vilstrup; Susanne Keiding
Journal:  Scand J Gastroenterol       Date:  2010-11-01       Impact factor: 2.423

2.  Hepatic galactose metabolism quantified in humans using 2-18F-fluoro-2-deoxy-D-galactose PET/CT.

Authors:  Michael Sørensen; Kasper Sandager Mikkelsen; Kim Frisch; Ludvik Bass; Bo Martin Bibby; Susanne Keiding
Journal:  J Nucl Med       Date:  2011-08-29       Impact factor: 10.057

Review 3.  Noninvasive assessment of liver function.

Authors:  Steve Helmke; Jordi Colmenero; Gregory T Everson
Journal:  Curr Opin Gastroenterol       Date:  2015-05       Impact factor: 3.287

4.  Determination of hepatic galactose elimination capacity using 2-[¹⁸F]fluoro-2-deoxy-D-galactose PET/CT: reproducibility of the method and metabolic heterogeneity in a normal pig liver model.

Authors:  Michael Sørensen
Journal:  Scand J Gastroenterol       Date:  2010-08-09       Impact factor: 2.423

5.  Effect of stereotactic body radiotherapy on regional metabolic liver function investigated in patients by dynamic [18F]FDGal PET/CT.

Authors:  Michael Sørensen; Mette Marie Fode; Jørgen Baltzer Petersen; Marianne Ingerslev Holt; Morten Høyer
Journal:  Radiat Oncol       Date:  2021-10-01       Impact factor: 3.481

Review 6.  Quantitative PET of liver functions.

Authors:  Susanne Keiding; Michael Sørensen; Kim Frisch; Lars C Gormsen; Ole Lajord Munk
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-04-25

7.  The galactose elimination capacity and mortality in 781 Danish patients with newly-diagnosed liver cirrhosis: a cohort study.

Authors:  Peter Jepsen; Hendrik Vilstrup; Peter Ott; Susanne Keiding; Per K Andersen; Niels Tygstrup
Journal:  BMC Gastroenterol       Date:  2009-06-30       Impact factor: 3.067

8.  Regional metabolic liver function measured in patients with cirrhosis by 2-[¹⁸F]fluoro-2-deoxy-D-galactose PET/CT.

Authors:  Michael Sørensen; Kasper S Mikkelsen; Kim Frisch; Gerda E Villadsen; Susanne Keiding
Journal:  J Hepatol       Date:  2013-01-20       Impact factor: 25.083

9.  Non-isotopic tyrosine kinetics using an alanyl-tyrosine dipeptide to assess graft function in liver transplant recipients - a pilot study.

Authors:  Claus G Krenn; Herwig Pokorny; Klaus Hoerauf; Josef Stark; Erich Roth; Heinz Steltzer; Wilfred Druml
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

10.  Hepatic uptake and metabolism of galactose can be quantified in vivo by 2-[18F]fluoro-2-deoxygalactose positron emission tomography.

Authors:  Michael Sørensen; Ole Lajord Munk; Frank Viborg Mortensen; Aage Kristian Olsen; Dirk Bender; Ludvik Bass; Susanne Keiding
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-05-15       Impact factor: 4.052

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.